Effect of Perioperative Interleukin-6 and Tumor Necrosis Factor-α on Long-Term Outcomes in Locally Advanced Gastric Cancer: Results from the CLASS-01 Trial.

Citation metadata

Publisher: Hindawi Limited
Document Type: Article
Length: 6,794 words
Lexile Measure: 1300L

Document controls

Main content

Abstract :

Background. Little is known about the relation between perioperative inflammatory changes and long-term survival in cancer patients. The aim of the study was to assess the association of perioperative serum interleukin-6 (IL6) and tumor necrosis factor-α (TNFα ) levels with the 5-year overall survival in locally advanced gastric cancer. Methods. The 135 eligible patients in one center of Nanfang Hospital were retrieved from CLASS-01 trial (NCT01609309), an open-label, multicenter, randomized clinical noninferiority trial conducted at 14 centers in China. Serum IL6 and TNFα levels were tested before surgery, and on postoperative day (POD) 1, POD3, and POD5, respectively, referring to IL6_0, IL6_1, IL6_3, and IL6_5 and TNFα _0, TNFα _1, TNFα _3, and TNFα _5. Kaplan-Meier methods and COX models were used for survival analysis. Results. High levels of IL6_0 (≥3.67pg/mL) and TNFα _0 (≥14.8pg/mL) presented worse disease-free survival (DFS) (P=0.0057 for IL6_0 and P=0.0014 for TNFα _0) and overall survival (OS) (P=0.0021 for IL6_0 and P=0.0019 for TNFα _0). Both high IL6_0 and high IL6_5 levels indicated worse prognosis than other combinations (P=0.0045 for DFS and P=0.0022 for OS). In multivariate analysis, both high IL6_0 and high IL6_5 levels were significantly associated with poor DFS (HR=4.29, 95% CI: 1.42-12.95, P=0.01) and OS (HR=4.11, 95% CI: 1.35-12.49, P=0.013) after adjustment of tumor stage and TNFα _0. Also, high IL6_5 level was identified as the independent-related factor for postoperative infectious complications (OR=2.69, 95% CI: 1.03-7.01, P=0.043). Conclusions. Perioperative high serum IL6 and TNFα levels are negatively associated with 5-year survival outcomes in patients with locally advanced gastric cancer, indicating the potential survival benefits from perioperative anti-inflammatory treatment.

Source Citation

Source Citation   

Gale Document Number: GALE|A710569454